AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27069173
Drug: Non-pre-hydration (non-Mg-hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pre-hydration (non-Mg-hydration group)
Trial: 19248130
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with infliximab
Trial: 19248130
Drug: Initial combination
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial combination therapy with prednisone
Trial: 17884605
Drug: Self-administered SCREEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered SCREEN II
Trial: 17884605
Drug: Telephone-administered SCREEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-administered SCREEN II
Trial: 11741732
Drug: Phosphoric acid
RxNorm normalized name: Phosphoric Acid
DrugBank: Phosphoric acid (DB09394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phosphoric acid gel for 60s
Trial: 7798679
Drug: Towne vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Towne vaccine (approximately 500 pfu)
Trial: 7798679
Drug: Towne vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Towne vaccine
Trial: 11527124
Drug: Bisoprolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (10 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Trial: 11527124
Drug: Acebutolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol (400 mg once a day for 8 weeks, dosage doubled after 4 weeks if DBP > 90 mm Hg)
Trial: 25471197
Drug: Caffeine (expected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (expected and administered)
Trial: 23429905
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (300 mL)
Trial: 22013793
Drug: Xinluotong Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinluotong Tablet (XLTT), four tablets each time, three times a day
Trial: 22013793
Drug: Yangxinshi Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi Tablet (YXST), three tablets each time, three times a day
Trial: 22013793
Drug: Xinluotong Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinluotong Tablet (XLTT)
Trial: 22013793
Drug: Yangxinshi Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yangxinshi Tablet (YXST)
Trial: 17938390
Drug: Aspirin, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin, 100 mg
Trial: 14607578
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (leuprolide acetate; 1 mg/d, SC)
Trial: 14607578
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA; 20 mg/d)
Trial: 29896798
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion to achieve target MAP of 75 mm Hg
Trial: 29896798
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion to achieve target MAP of 90 mm Hg
Trial: 29896798
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion to achieve target MAP of 60 mm Hg
Trial: 25730591
Drug: Dance Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance Movement Therapy (DMT) during radiotherapy (6 sessions at 90 minutes each)
Trial: 25730591
Drug: Dance Movement
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dance Movement Therapy (DMT) after radiotherapy (1 to 2 months post-treatment)
Trial: 24668261
Drug: Harp therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harp therapy during embryo transfer
Trial: 24668261
Drug: Harp therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harp therapy
Trial: 23412077
Drug: Intensive participants
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive participants who never took insulin or TZD
Trial: 23412077
Drug: Intensive participants
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive participants who began insulin or TZD after enrollment
Trial: 19941160
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg) for 12 weeks followed by Anastrozole (1 mg) for 12 weeks
Trial: 19941160
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg) for 12 weeks followed by Letrozole (2.5 mg) for 12 weeks
Trial: 19941160
Drug: Tamoxifen (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (after 6 months of AI therapy)
Trial: 19941160
Drug: Prior Tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior Tamoxifen therapy
Trial: 1793238
Drug: HeNe laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HeNe laser treatment (wave-length, 632.8 nm; beam power, 6 mW; continuous emission, energy density, 4 J/cm2)
Trial: 1793238
Drug: Placebo HeNe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HeNe laser treatment
Trial: 6430689
Drug: Compliance-improving strategies
RxNorm normalized name: ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Compliance-improving strategies (patient counselling, special medication container, self-recording of medication intake and seizures, mailed reminders)
Trial: 30803749
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (4 g daily for 8 weeks)
Trial: 29396070
Drug: l-homoarginine (l-hArg)
DrugBank: L-homoarginine (DB03974)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-homoarginine (l-hArg) supplementation
Trial: 26792024
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of HCA (2800 mg in water)
Trial: 17971533
Drug: Adaptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive treatment strategies
Trial: 17971533
Drug: Sequential randomization
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential randomization
Trial: 15576850
Drug: PON1 genotypes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PON1 genotypes (L55M, Q192R, -107C/T, -162A/G, -824G/A, and -907G/C)
Trial: 8897081
Drug: Sucralfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (2 g b.i.d. for 5 days)
Trial: 1642342
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg intravenous bolus of dexamethasone
Trial: 6427477
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg luteinizing hormone releasing hormone agonist daily
Trial: 6427477
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg diethylstilbestrol per day
Trial: 29327313
Drug: Somatosensory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatosensory therapy (four types of exercises: touch, proprioception, vibration, stereognosis)
Trial: 29327313
Drug: Somatosensory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatosensory therapy
Trial: 26785711
Drug: Calorie-restricted, semi-vegetarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements (fish oil, lipoic acid, omega-3 polyunsaturated fatty acids, resveratrol, multivitamin complex)
Trial: 26785711
Drug: Calorie-restricted, semi-vegetarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calorie-restricted, semi-vegetarian diet with vitamin D and dietary supplements
Trial: 26785711
Drug: Weekly administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly administration of 5000 IU vitamin D
Trial: 2318913
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide suppositories (150 mg)
Trial: 2318913
Drug: Intravenous metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoclopramide (150 mg)
Trial: 2318913
Drug: High-dose metoclopramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metoclopramide suppositories
Trial: 381860
Drug: Metoprolol (234
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (234 +/- 22 mg/day)
Trial: 381860
Drug: Pindolol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (25 +/- 2 mg/day)
Trial: 31471863
Drug: BAL101553 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL101553 administered as a 48-h IV infusion at a maximum tolerated dose (MTD) of 70 mg/m2
Trial: 31471863
Drug: BAL101553 oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAL101553 oral administration on Days 15–21 of cycle 2
Trial: 28988746
Drug: Alfaxalone 2
RxNorm normalized name: alfaxalone
DrugBank: Alfaxalone (DB11371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 2 mg kg−1 (A2)
Trial: 28988746
Drug: Alfaxalone 1
RxNorm normalized name: alfaxalone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 1 mg kg−1 (A1)
Trial: 28988746
Drug: Saline 0.1
RxNorm normalized name: Simply Saline 0.154 MEQ/ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.1 mL kg−1 (S)
Trial: 28988746
Drug: Alfaxalone 1
RxNorm normalized name: alfaxalone 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfaxalone 1 mg kg−1 (A1) and Alfaxalone 2 mg kg−1 (A2)
Trial: 11789085
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg micronized E2 daily
Trial: 4147246
Drug: Ro 3‐3528,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 3‐3528, a non‐selective β‐adrenoceptor blocking drug
Trial: 28425575
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (9 of 50000 IU cholecalciferol capsules for 9 weeks taken at weekly intervals)
Trial: 27979579
Drug: Liraglutide (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (0.6 mg with weekly increase to 3.0 mg for the last week)
Trial: 17920501
Drug: Full orthodontic
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full orthodontic treatment (after phase 1)
Trial: 7834993
Drug: 6 h
RxNorm normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 h primed constant infusion of NaH13CO3 combined with a euglycaemic hyperinsulinaemic clamp for the last 3 h (study 1)
Trial: 7834993
Drug: 6 h
RxNorm normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 h primed constant infusion of NaH13CO3 alone (study 2)
Trial: 7834993
Drug: 6 h
RxNorm normalized name: 1-36 hpthrp
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 h infusion of normal saline combined with a hyperinsulinaemic clamp for the last 3 h (study 3)
Trial: 3046537
Drug: Inhaled beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beta agonist
Trial: 30283403
Drug: Melatonin 2
RxNorm normalized name: melatonin 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 2 mg BD
Trial: 30283403
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg BD
Trial: 30283403
Drug: Melatonin 8
RxNorm normalized name: Calcium Carbonate/Melatonin 84 MG-5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 8 mg BD
Trial: 30283403
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of melatonin combined
Trial: 27188688
Drug: Mixed-gender Body
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed-gender Body Project (MG)
Trial: 24754974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (systemic and narrative group psychotherapy) with feedback intervention
Trial: 24754974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment only (no feedback)
Trial: 24754974
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with feedback intervention
Trial: 14964737
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (0.1 mg/kg) with control (saline)
Trial: 7524921
Drug: Retroperitoneal lymph-node
RxNorm normalized name: Bos taurus lymph preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retroperitoneal lymph-node dissection (RPLND) without adjuvant chemotherapy
Trial: 7524921
Drug: Overall survival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall survival with cisplatin-based chemotherapy
Trial: 29194180
Drug: No ADL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No ADL retraining in PTA (treatment as usual, TAU)
Trial: 24024319
Drug: Dongchongxiacao (Cordyceps)
RxNorm normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dongchongxiacao (Cordyceps) treatment (n = 52)
Trial: 24024319
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic treatment (n = 51)
Trial: 18412647
Drug: Lidocaine 0.5
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.5 mg x kg(‐1)
Trial: 8768815
Drug: Terbinafine cream
RxNorm normalized name: terbinafine Topical Cream
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Terbinafine cream during 1 week
Trial: 8768815
Drug: Miconazole cream
RxNorm normalized name: Miconazole Nitrate 2% Topical application Cream [CAREALL MICONAZOLE CREAM]
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole cream during 4 weeks
Trial: 18308903
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation program (24 hours of computerized practice over a 12-week period and a weekly discussion group)
Trial: 15983466
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% amitriptyline
Trial: 15983466
Drug: Topical 1%
RxNorm normalized name: fluoride topical 1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1% ketamine
Trial: 15983466
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% amitriptyline-1% ketamine combined
Trial: 12406832
Drug: Montelukast (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (5 mg chewable tablets)
Trial: 10521866
Drug: Screening intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screening intervention (not specified dosage or duration)
Trial: 7723712
Drug: Intracoronary dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary dipyridamole infusion
Trial: 7283216
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg epinephrine
Trial: 7283216
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg epinephrine
Trial: 7283216
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg epinephrine
Trial: 20215923
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (LDX) treatment
Trial: 26054141
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (budesonide nasal spray and cetirizine tablets)
Trial: 17556718
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (Control) for 4 months
Trial: 15218357
Drug: Decrease of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of HER-2/neu ECD levels after three courses of therapy
Trial: 2700362
Drug: S +
RxNorm normalized name: K-Y Yours + Mine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S + A (PT-01 treatment combined with scaling)
Trial: 21402982
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of autologous plasmin enzyme (APE), 0.2 mL
Trial: 17038056
Drug: Normal dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal dose of 1% chlorhexidine gel
Trial: 17038056
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of chlorhexidine gel and whitening dentifrice
Trial: 9068264
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day atenolol
Trial: 9068264
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day celiprolol
Trial: 9068264
Drug: 80 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/day isosorbide dinitrate
Trial: 3462014
Drug: Cladosporium herbarum
RxNorm normalized name: CLADOSPORIUM HERBARUM
DrugBank: Cladosporium herbarum (DB10865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladosporium herbarum inhalation (1:100000, 1:10000, 1:1000, 1:100 w/v)
Trial: 3462014
Drug: Histamine inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine inhalation (0.3, 0.6, 1.2, 2.4 mg/ml)
Trial: 20229169
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg UFT alone (control)
Trial: 17660032
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 800 IU of vitamin E alpha daily
Trial: 12787300
Drug: fexofenadine 30
RxNorm normalized name: fexofenadine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fexofenadine 30 mg
Trial: 8876706
Drug: 320 mg
RxNorm normalized name: aspirin 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 320 mg Permixon
Trial: 1850811
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy after initial resection
Trial: 1850811
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy followed by resection
Trial: 1850811
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chemotherapy and radiotherapy (non-surgical patients)
Trial: 1850811
Drug: Postoperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative chemotherapy only (for stage III patients)
Trial: 6218789
Drug: Clonidine hydrochloride,
RxNorm normalized name: CloNIDine Hydrochloride, compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine hydrochloride, 0.05 mg, orally twice daily for two weeks
Trial: 30332920
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity testing before chemotherapy and during febrile neutropenia
Trial: 30332920
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity testing in patients with documented site of infection
Trial: 30332920
Drug: Overall assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall assessment of insulin sensitivity and hospitalization outcome
Trial: 26810999
Drug: Daily intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravenous human albumin solution infusions for up to 14 days or until discharge, based on serum albumin levels.
Trial: 22218376
Drug: Single intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of 2.5 mL of low-molecular-weight, non-cross-linked hyaluronic acid
Trial: 22218376
Drug: Single intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intra-articular injection of 2.5 mL of normal saline solution (placebo)
Trial: 7777350
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, n=23)